KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Short-term Investments (2018 - 2025)

Aurinia Pharmaceuticals' Short-term Investments history spans 6 years, with the latest figure at $317.8 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 15.54% year-over-year to $317.8 million; the TTM value through Dec 2025 reached $317.8 million, up 15.54%, while the annual FY2025 figure was $317.8 million, 15.54% up from the prior year.
  • Short-term Investments reached $317.8 million in Q4 2025 per AUPH's latest filing, up from $278.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $317.8 million in Q4 2025 to a low of $191.7 million in Q1 2021.
  • Average Short-term Investments over 5 years is $267.1 million, with a median of $273.8 million recorded in 2023.
  • Peak YoY movement for Short-term Investments: skyrocketed 49.33% in 2022, then dropped 11.76% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $234.2 million in 2021, then grew by 26.07% to $295.2 million in 2022, then increased by 2.17% to $301.6 million in 2023, then dropped by 8.81% to $275.0 million in 2024, then grew by 15.54% to $317.8 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Short-term Investments are $317.8 million (Q4 2025), $278.6 million (Q3 2025), and $262.1 million (Q2 2025).